231 related articles for article (PubMed ID: 16164393)
1. Infections associated with tumor necrosis factor-alpha antagonists.
Rychly DJ; DiPiro JT
Pharmacotherapy; 2005 Sep; 25(9):1181-92. PubMed ID: 16164393
[TBL] [Abstract][Full Text] [Related]
2. Problems encountered during anti-tumour necrosis factor therapy.
Desai SB; Furst DE
Best Pract Res Clin Rheumatol; 2006 Aug; 20(4):757-90. PubMed ID: 16979537
[TBL] [Abstract][Full Text] [Related]
3. Differences between anti-tumor necrosis factor-alpha monoclonal antibodies and soluble TNF receptors in host defense impairment.
Dinarello CA
J Rheumatol Suppl; 2005 Mar; 74():40-7. PubMed ID: 15742464
[TBL] [Abstract][Full Text] [Related]
4. Drug-specific risk of non-tuberculosis opportunistic infections in patients receiving anti-TNF therapy reported to the 3-year prospective French RATIO registry.
Salmon-Ceron D; Tubach F; Lortholary O; Chosidow O; Bretagne S; Nicolas N; Cuillerier E; Fautrel B; Michelet C; Morel J; Puéchal X; Wendling D; Lemann M; Ravaud P; Mariette X;
Ann Rheum Dis; 2011 Apr; 70(4):616-23. PubMed ID: 21177290
[TBL] [Abstract][Full Text] [Related]
5. Tuberculosis infections and tumor necrosis factor alpha antagonists.
Gan J; Manadan AM; Sequiera W; Block JA
Am J Ther; 2013 Jan; 20(1):73-8. PubMed ID: 21519217
[TBL] [Abstract][Full Text] [Related]
6. Serious infections associated with anticytokine therapies in the rheumatic diseases.
Giles JT; Bathon JM
J Intensive Care Med; 2004; 19(6):320-34. PubMed ID: 15523118
[TBL] [Abstract][Full Text] [Related]
7. Fungal infections complicating tumor necrosis factor alpha blockade therapy.
Tsiodras S; Samonis G; Boumpas DT; Kontoyiannis DP
Mayo Clin Proc; 2008 Feb; 83(2):181-94. PubMed ID: 18241628
[TBL] [Abstract][Full Text] [Related]
8. Risk of tuberculosis in patients treated with tumor necrosis factor antagonists due to incomplete prevention of reactivation of latent infection.
Gómez-Reino JJ; Carmona L; Angel Descalzo M;
Arthritis Rheum; 2007 Jun; 57(5):756-61. PubMed ID: 17530674
[TBL] [Abstract][Full Text] [Related]
9. Cancer risk with tumor necrosis factor alpha (TNF) inhibitors: meta-analysis of randomized controlled trials of adalimumab, etanercept, and infliximab using patient level data.
Askling J; Fahrbach K; Nordstrom B; Ross S; Schmid CH; Symmons D
Pharmacoepidemiol Drug Saf; 2011 Feb; 20(2):119-30. PubMed ID: 21254282
[TBL] [Abstract][Full Text] [Related]
10. Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumor necrosis factor antagonists.
Carmona L; Gómez-Reino JJ; Rodríguez-Valverde V; Montero D; Pascual-Gómez E; Mola EM; Carreño L; Figueroa M;
Arthritis Rheum; 2005 Jun; 52(6):1766-72. PubMed ID: 15934089
[TBL] [Abstract][Full Text] [Related]
11. Risk and prevention of tuberculosis and other serious opportunistic infections associated with the inhibition of tumor necrosis factor.
Winthrop KL
Nat Clin Pract Rheumatol; 2006 Nov; 2(11):602-10. PubMed ID: 17075599
[TBL] [Abstract][Full Text] [Related]
12. The infectious profiles of anti-tumor necrosis factor agents in a Thai population: a retrospective study a the university-based hospital.
Suwannalai P; Auethavekiat P; Udomsubpayakul U; Janvitayanujit S
Int J Rheum Dis; 2009 Jul; 12(2):118-24. PubMed ID: 20374328
[TBL] [Abstract][Full Text] [Related]
13. Pregnancy in rheumatology patients exposed to anti-tumour necrosis factor (TNF)-alpha therapy.
Roux CH; Brocq O; Breuil V; Albert C; Euller-Ziegler L
Rheumatology (Oxford); 2007 Apr; 46(4):695-8. PubMed ID: 17158212
[TBL] [Abstract][Full Text] [Related]
14. Granulomatous infectious diseases associated with tumor necrosis factor antagonists.
Wallis RS; Broder MS; Wong JY; Hanson ME; Beenhouwer DO
Clin Infect Dis; 2004 May; 38(9):1261-5. PubMed ID: 15127338
[TBL] [Abstract][Full Text] [Related]
15. Skin lesions and treatment with tumor necrosis factor alpha antagonists.
Hernández MV; Meineri M; Sanmartí R
Reumatol Clin; 2013; 9(1):53-61. PubMed ID: 22766431
[TBL] [Abstract][Full Text] [Related]
16. Safety of biologic therapies--an update.
Keystone EC
J Rheumatol Suppl; 2005 Mar; 74():8-12. PubMed ID: 15742458
[TBL] [Abstract][Full Text] [Related]
17. TNF-blocking agents and tuberculosis: new drugs illuminate an old topic.
Keane J
Rheumatology (Oxford); 2005 Jun; 44(6):714-20. PubMed ID: 15741198
[TBL] [Abstract][Full Text] [Related]
18. [Guidelines of the Israeli association of rheumatology for the prevention of tuberculosis in patients treated with TNF-alpha blockers].
Elkayam O; Balbir-Gurman A; Lidgi M; Rahav G; Weiler-Ravel D
Harefuah; 2007 Mar; 146(3):235-7, 244. PubMed ID: 17460934
[TBL] [Abstract][Full Text] [Related]
19. Histoplasmosis after treatment with anti-tumor necrosis factor-alpha therapy.
Wood KL; Hage CA; Knox KS; Kleiman MB; Sannuti A; Day RB; Wheat LJ; Twigg HL
Am J Respir Crit Care Med; 2003 May; 167(9):1279-82. PubMed ID: 12615627
[TBL] [Abstract][Full Text] [Related]
20. Life-threatening histoplasmosis complicating immunotherapy with tumor necrosis factor alpha antagonists infliximab and etanercept.
Lee JH; Slifman NR; Gershon SK; Edwards ET; Schwieterman WD; Siegel JN; Wise RP; Brown SL; Udall JN; Braun MM
Arthritis Rheum; 2002 Oct; 46(10):2565-70. PubMed ID: 12384912
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]